| Sign In to gain access to subscriptions and/or personal tools. |
Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis ComplexDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center, Houston, Texas, mary.k.koenig{at}uth.tmc.edu
Department of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center, Houston, Texas
Department of Pediatrics, Division of Medical Genetics, The University of Texas Health Science Center, Houston, Texas
The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2
Key Words: subependymal giant cell astrocytoma • tuberous sclerosis complex • rapamycin • astrocytoma References
Journal of Child Neurology, Vol. 23, No. 10,
1238-1239 (2008)
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.